Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide Following CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory CD19+ B-Cell Leukemias and Lymphomas
NCT07532525Phase 1Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pomalidomide in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Incidence of adverse events at 56 days. Started Aug 2026; status: recruiting.
02
Drugs
pomalidomide
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07532525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07532525.